CDKN1B and urinary bladder cancer: Five of the 26 SMGs had not been reported as SMGs in bladder cancer in previous studies [4, 6, 7, 8]: CDKN1B (1.2%), ITK (1.8%), PRDM2 (3.1%), FOXA1 (2.7%), and BAP1 (1.8%).